Confirmed tumor response as measured by RECIST criteria Up to 5 years [clinicaltrials_resource:0002564904e6e9a71837310686cbf2ac]
Patients receive docetaxel IV over 1 hour followed by irinotecan IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses beyond CR.
Patients are followed every 2 months until disease progression and then every 6 months thereafter.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Confirmed tumor response as measured by RECIST criteria Up to 5 years [clinicaltrials_resource:0002564904e6e9a71837310686cbf2ac]
Patients receive docetaxel IV over 1 hour followed by irinotecan IV over 1 hour on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) receive 2 additional courses beyond CR.
Patients are followed every 2 months until disease progression and then every 6 months thereafter.
Bio2RDF identifier
0002564904e6e9a71837310686cbf2ac
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0002564904e6e9a71837310686cbf2ac
measure [clinicaltrials_vocabulary:measure]
Confirmed tumor response as measured by RECIST criteria
time frame [clinicaltrials_vocabulary:time-frame]
Up to 5 years
description
Patients receive docetaxel IV ...... hen every 6 months thereafter.
identifier
clinicaltrials_resource:0002564904e6e9a71837310686cbf2ac
title
Confirmed tumor response as measured by RECIST criteria Up to 5 years
@en
type
label
Confirmed tumor response as me ...... 2564904e6e9a71837310686cbf2ac]
@en